Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Kwasi Kwarteng STILL supports 'general direction' of his economy-destroying mini budget

Former Chancellor of the Exchequer Kwasi Kwarteng is sticking by the "general direction" of his mini budget that crashed the UK economy, but admits that he has regrets

Daily Mirror

RMT strikes to continue, says Mick Lynch, after members reject ‘dreadful’ pay offers – as it happened

RMT general secretary says members could not accept offer he says would make railways less safe

The Guardian - UK

Take AstraZeneca’s warning seriously. The UK is missing out in life sciences

Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth

AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance.

Investors Business Daily

Dow Jones Rallies 250 Points After Jobless Claims; Disney Surges On Earnings

The Dow Jones rallied 250 points Thursday after weekly first-time jobless claims. Disney shares surged on earnings results.

Investors Business Daily

End of vaccine boost for AstraZeneca as it looks elsewhere for growth

The firm made just shy of $4 billion from sales of its Covid-19 vaccine in 2021, but sales have since more than halved and were down 95% at the tail end of last year

Evening Standard

FTSE 100 Live: Unilever price warning, AstraZeneca and BAT post results

Blue-chip companies Unilever, AstraZeneca and British American Tobacco today lead a busy session for end-of-year corporate earnings.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

A technicality could withhold RSV shots

A glitch in a law may make it difficult for children from low-income families to get the new RSV vaccine

Salon

A single-shot treatment to protect infants from RSV may be coming soon

The illness sends tens of thousands of babies to the hospital each year. If approved, the new injection would be the first broadly available prevention tool.

WEKU

Health department reviewing fifth COVID-19 vaccine. But what if you have missed a dose?

The health department is expected to make a decision on the fifth dose within weeks. Here's what we know so far.

ABC News

ATAGI is considering a fifth COVID-19 vaccine dose, but how many boosters should I already have and who is eligible?

The federal government is waiting on advice about whether Australians should have a fifth COVID-19 vaccine. So, how many people have had the current boosters and who is eligible for what?

ABC News

How anti-vaccine misinformation hampers conversation about genuine concerns

With more than 13 billion doses administered to date, we know Covid vaccines are overwhelmingly safe, effective,

Wales Online

Andrew Bridgen: how anti-vaccine misinformation hampers the conversation about genuine vaccine injuries

MP Andrew Bridgen was suspended from the Conservative party on January 11 for persistent misinformation about COVID vaccines, including numerous false claims around their safety. The final straw appears to have been his comments comparing the vaccination programme to the Holocaust.

The Conversation

Stock Market Holds Gains; Chip Stock Breaks Out

The stock market held afternoon gains as a server and storage stock flashed a sell signal. Air pollution control stock broke out of a base.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout

AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.

Investors Business Daily

AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal

AstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion.

Investors Business Daily

IBD 50 Stocks To Watch: Pharmaceutical Leader AstraZeneca Retakes Latest Buy Point

Among the top stocks to watch, pharmaceutical leader AstraZeneca is retaking its latest buy point despite Tuesday's stock market weakness.

Bangkok Post

Gradual arrival of Chinese expected, no Covid test, says Anutin

Public Health Minister Anutin Charnvirakul does not expect a sudden influx of Chinese tourists or see a need for any special arrival rules for them.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

How common are severe side effects from COVID vaccines? And how are they detected?

Former federal MP Dr Kerryn Phelps has talked this week about the medical problems she and her wife had after their COVID-19 vaccinations around 18 months ago.

Bangkok Post

Korean jab maker scouts Asean links

SEOUL: A South Korean company is looking for a business opportunity with partners from the Association of Southeast Asian Nations (Asean) to help develop the regional market for its Covid-19 vaccine.

The Independent UK

Covid vaccine concerns were overblown, says AstraZeneca boss as he is knighted

Sir Pascal Soriot was speaking after he was knighted by the King at Windsor Castle on Wednesday.

Investors Business Daily

AstraZeneca Stock Hits New Relative Strength Highs, Reaches Buy Zone

AstraZeneca is breaking out on the strength of its relative strength highs and as profits continue to grow.

The Independent UK

Scientists hail ‘landmark moment’ in the treatment of advanced breast cancer

Capivasertib is being made by pharmaceutical giant AstraZeneca following a programme of drug discovery research at the Institute of Cancer Research.

The Independent UK

‘Landmark moment’ in breast cancer treatment could save thousands of lives each year

‘The treatment is far less debilitating than chemotherapy and I’ve been given the gift of a longer life,’ says one patient

Tribune News Service

The business of clinical trials is booming. Private equity has taken notice

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.